GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Net Cash per Share

Tourmaline Bio (Tourmaline Bio) Net Cash per Share : $9.72 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Tourmaline Bio's Net Cash per Share for the quarter that ended in Dec. 2023 was $9.72.

The historical rank and industry rank for Tourmaline Bio's Net Cash per Share or its related term are showing as below:

TRML' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.49   Med: 2.69   Max: 2.69
Current: 1.49

During the past 3 years, the highest Price-to-Net-Cash Ratio of Tourmaline Bio was 2.69. The lowest was 1.49. And the median was 2.69.

TRML's Price-to-Net-Cash is ranked better than
79.14% of 863 companies
in the Biotechnology industry
Industry Median: 4.14 vs TRML: 1.49

Tourmaline Bio Net Cash per Share Historical Data

The historical data trend for Tourmaline Bio's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Net Cash per Share Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Net Cash per Share
- -1.01 9.72

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial - -1.01 -2.31 6.83 9.72

Competitive Comparison of Tourmaline Bio's Net Cash per Share

For the Biotechnology subindustry, Tourmaline Bio's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Price-to-Net-Cash falls into.


Tourmaline Bio Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Tourmaline Bio's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(202.951-5.253-0)/20.3376
=9.72

Tourmaline Bio's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(202.951-5.253-0)/20.3376
=9.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio  (NAS:TRML) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Tourmaline Bio Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Net Cash per Share
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.